

---

Literatur

1. Spagnolo P, Balestro E, Aliberti S et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? *Lancet Respir Med.* 2020;8:750-2
2. Zumla A, Hui DS, Azhar El et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. *Lancet* 2020;395:e35-e36
3. Ojo AS, Balogun SA, Williams OT et al. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. 2020; <https://doi.org/10.1155/2020/6175964>
4. Travis WD, Costabel U, Hansell DM et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med.* 2013;188:733-48
5. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. *Lancet Respir Med.* 2020;8:807-15
6. WHO. Corticosteroids for COVID-19 - Living Guidance. <https://www-world-health-organization-who-international-organization-for-legal-medical-sciences-and-technology-publications-publications-i/item/WHO-2019-nCoV-Corticosteroids-20201> 2020. aufgerufen 29.3.2021
7. Behr J, Günther A, Ammenwerth W et al. S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose. *Pneumologie.* 2013;67:81-111
8. Biondini D, Balestro E, Sverzellati N et al. Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies. *Expert Rev Respir Med.* 2020;14(4):405-414
9. Hutchinson J, Fogarty A, Hubbard R et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. *Eur Respir J.* 2015;46:795-806